Krystal, PeriphaGen in Settlement on Trade Secret Litigation

Krystal Biotech reached a binding term sheet with PeriphaGen to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020, the company announced Tuesday.

• Krystal will receive all of PeriphaGen’s biological materials and skin assets and will pay PeriphaGen $25 million within 10 days of the completion of a Final Settlement Agreement
  • Upon approval of Krystal’s first product by the FDA, Krystal will pay an additional $12.5 million, followed by three additional $12.5 million dollar milestone payments upon reaching $100 million in total cumulative sales, $200 million in total cumulative sales and $300 million in ...